Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16751263 | 0.82 | CYP3A4 (0.42) | CYP3A4CYP2C19GAAALDH1A1LMNA | |
| SCHEMBL11668486 | 0.79 | ALDH1A1 (0.40) | CYP3A4CYP2C19GAAALDH1A1LMNA | |
| SCHEMBL16751262 | 0.77 | CYP3A4 (0.40) | CYP3A4CYP2C19GAAALDH1A1LMNA | |
| SCHEMBL16573686 | 0.77 | CYP3A4 (0.47) | CYP3A4CYP2C19GAAALDH1A1LMNA | |
| SCHEMBL12907779 | 0.77 | CYP3A4 (0.47) | CYP3A4CYP2C19GAAALDH1A1LMNA | |
| SCHEMBL17931492 | 0.76 | TSHR (0.39) | CYP3A4CYP2C19GAAALDH1A1LMNA | |
| SCHEMBL234393 | 0.75 | KISS1R (0.46) | ALDH1A1HTTRAB9AATMMAPT | |
| Iodide SCHEMBL16599304 | 0.75 | TSHR (0.38) | CYP3A4CYP2C19GAAALDH1A1LMNA | |
| SCHEMBL18410487 | 0.74 | CYP3A4 (0.56) | CYP3A4CYP2C19GAAALDH1A1LMNA | |
| SCHEMBL3910323 | 0.74 | RAB9A (0.39) | GAAALDH1A1LMNAHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3071565-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | Auspex Pharmaceuticals, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-3049087-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | Auspex Pharmaceuticals, Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20160207917-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160207917-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160207917-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| WO-2015077520-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077520-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077521-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077521-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015048370-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015048370-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | PYGM, TNNC1, MUSK | CYP3A4 3999/4885CYP2C19 3284/4885GAA 40/4885 |
| US-20160207917-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | SULT2A1, CPT1A, SLC18A2 | CYP3A4 454/4885CYP2C19 252/4885GAA 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.